Chinese Academy of Sciences

Other

Micron Technology Incorporated

Shanghai Techwell Biopharmaceutical Co., Ltd.

Shanghai Haihe Pharmaceutical Co., Ltd.

International Business Machines Corporation

Intel Corporation

Sap Se

Otis Elevator Company

Shanghai Kanda Biotechnology Co, Ltd.

East China Normal University

Jiangsu Kanion Pharmaceutical Co., Ltd.

Cisen Pharmaceutical Co., Ltd.

Nanjing Luyesike Pharmaceutical Co., Ltd.

Shpp Global Technologies B.v.

Yi Chen

Jian Ding

Meiyu Geng

Chunhao Yang

Cun Tan

Xiaoming Ji

Zeling Cai

Shidong Liu

Xiang Wang

Zhaoli Zhang

Zehong Miao

Linghua Meng

Yukiyasu Murakami

Jing Xu

Lei Li

Qiong Zhang

Yihua Zhang

Jian Luo

Ke Yang

Xiaoliang Gao

Zheng-Wei Wang

Yanhong Chen

Jin Lei Ding

Jiapeng Li

Weizhong Qiu

Du Xue

Xiajuan Huan

Dan Qing Sha

Murilo Bonilha

Huizi Liu

Jing Long Zhang

Keith E Winters

Xuxing Chen

Qianqian Shen

Yucai Yao

Jian Li

Shuhui Chen

Zhi Hu Wang

Jing Li

Wei Zhou

Wei Lu

Min Huang

Sriram Kolinjivadi Padmanabhan

Yan Li

Rajesh Ramkrishna Bordawekar

Bin Xing

Min Fang

Jia Tao Li

Vinod Sharma

George Andrei Mihaila

Lei Jiang

Malini Krishnan Bhandaru

Lingyun Wu

Fajun Nan

Yuan Zhou

Yubo Zhou

Xiao Yan

Xi Zhang

Ke Ding

Ke Yu

Meng Wang

Jing Xiong

Yangming Zhang

Jing Ai

Hui Gu

Wen Jiang

Mingbo Su

Zhengchao Tu

Lechong Chen

Anhui Gao

Ao Zhang

Xiongbin Xu

Zhonghao Zhuo

Jianfeng Mei

Qiang Ma

Cailin Wang

Heng Wu

Zilan Song

Xiusheng Wang

Yan Du

Hua Xie

Xiaomei Ren

Wei Lv

Jianhua Cao

Gang Qiang

Yi Zhang

Qian He

Weiwei Li

Qingyun Jiang

Xun Huang

Chaojun Gong

Zhao Zhao

Shuai Tang

Kai Zheng

Li Na Yuan

Jinxue He

Liping Lin

Uma Maheswara Rao Gangumalla

Disclosed is a class of porcupine inhibitors, specifically a compound as represented by formula (I), and a pharmaceutically acceptable salt or an isomer thereof.

Compound as porcupine inhibitor and use thereof

Provided is an antibody-tumor necrosis factor α fusion protein and its preparation and applications. Specifically, the present disclosure relates to a fusion protein comprising an antibody moiety and a TNFα moiety, a nucleic acid molecule encoding same, a nucleic acid construct, a host cell and a method of production thereof, as well as applications of these materials in prevention and/or treatment of tumors.

Antibody-TNF α fusion protein and its preparation and applications

A robotic arm for minimally invasive surgery, comprising: a support mechanism, with a support base and a distal end connected by a movable connector; a posture adjustment mechanism with a rotation and pitching member rotatably connected to the distal end. The end of the rotation and pitching member is rotatably provided with an instrument base. A first rotation axis of the rotation and pitching member and a second rotation axis of the instrument base intersect at the remote center of motion. The rotation and pitching member drives the instrument base to pitch. An instrument driving mechanism is connected to the instrument base to install and drive surgical instruments. The robotic arm adopts a single-arm structure and is suitable for minimally invasive surgeries such as single-port or few-port surgeries. Flexible and free spatial posture adjustment like deflection, pitching, and rolling of the instrument base are achieved.

Robotic arm for minimally invasive surgery

A terminal mechanism of a surgical robot and control method and related equipment thereof. The control method comprises: generating a pose adjustment signal upon a remote center of motion and a spatial target point, for a robotic arm to drive an instrument base until the remote center of motion coincides with the target point; generating an extension signal for a positioning link to extend until the distal center of a channel member coincides with the remote center of motion; monitoring an installation completion signal of an surgical instrument at an instrument driving mechanism, and if yes, generating an instrument movement signal to move the surgical instrument to the target position. The surgical robot is suitable for few-port or single-port surgery. By controlling its terminal mechanism, interferences of end components are avoided, control accuracy is improved, and stability and availability is ensured.

Terminal mechanism of surgical robot and control method and related equipment thereof

A method of this disclosure may include performing a named entity recognition on text information related to requirements for a wireframe by a first artificial intelligence (AI) model, so as to extract entities and relations of the entities from the text information. The method may further comprise inputting the extracted entities and relations to a second AI model to generate the wireframe, wherein the second AI model is trained so that a difference between resultant relations of the entities of the generated wireframe and the extracted relations of the entities from the first AI model is decreased.

Wireframe generation

An elevator interactive terminal and an elevator interactive system. The elevator interactive system of the present invention comprises an elevator interactive terminal, configured with a social communication media module, wherein a user is registered as a first registered user in the social communication media module; and a server coupled to a communication bus of an elevator system, configured with the social communication media module and to register an elevator as the second registered user in the social communication media module, wherein, based on the social communication media module, interactive communication is performed between the first registered user on the elevator interactive terminal corresponding to the user and the second registered user on the server corresponding to the elevator.

Interaction terminal and system for elevator

The invention provides an indolizine compound represented by formula I or a pharmaceutically acceptable salt thereof, a preparation method and a use thereof. The indolizine compound has an inhibitory effect on wild-type and/or mutant EZH2 or EZH1, and is expected to be developed into a novel drug for anti-tumor or for the treatment of autoimmune diseases. 

Indolizine compounds, preparation method and use thereof

The present utility model discloses a MFi-certified digital data cable comprising a wire rod which is equipped with an input connector at one end and an output connector at the other end; the output connector comprises a MFi-certified connector, a circuit board, a Nixie tube and a rubber base; a connecting piece is fixed at the position adjoining the tail-end of the MFi-certified connector; a plurality of conductive terminals are fixed inside the connecting piece, two ends of each conductive terminal pass through two ends of the connecting piece and then are connected with the MFi-certified connector and the circuit board respectively so the circuit board is assembled and fixed via the connecting piece.

MFi-certified digital data cable

Described embodiments include memory systems that may shadow certain data stored in a first memory device (e.g. NAND flash device) onto a second memory device (e.g. DRAM device). Memory systems may train and/or re-organize stored data to facilitate the selection of data to be shadowed. Initial responses to memory commands may be serviced from the first memory device, which may have a lower latency than the second memory device. The remaining data may be serviced from the second memory device. A controller may begin to access the remaining data while the initial response is being provided from the first memory device, which may reduce the apparent latency associated with the second memory device.

Memory systems and methods including training, data organizing, and/or shadowing

The invention relates to a compound of formula (I): wherein variables are as defined in the specification. The compound is an inhibitor of an ERK kinase, e.g. ERK1 and/or ERK2 kinase. The invention also relates to the use of the compound and a method for preparing the compound, and a pharmaceutical composition containing the compound.

Compound having ERK kinase inhibitory activity and use thereof

The present disclosure involves systems, software, and computer implemented methods for performing dynamic topology switch in a failover operation. In one example, a failover of a first node is determined. The first node includes a first data server and a first replication server. At least one user application connects to the first data server prior to the failover of the first node. In response to the determined failover, the at least one user application is connected to a second data server of a second node. The second node includes the second data server and a second replication server. Prior to the failover of the first node, a data replication topology of the second node is a remote topology. During the failover, if the first replication server on the first node is down, the data replication topology of the second node is switched from the remote topology to a local topology.

Dynamic topology switch for data replication

The present disclosure relates to 7-substituted pyrrolo[2,1-f][1,2,4]triazine compounds or pharmaceutically acceptable salts thereof, and preparation methods and uses thereof. These compounds show good PI3K inhibitory activity, can effectively inhibit the activity of PI3K kinase, and has significant enhancement and improvement of pharmacokinetic properties, such as bioavailability, due to the introduction of the 7-position group; furthermore, the compounds of the present disclosure exhibit an unpredictable high selectivity and strong inhibitory activity on PI3K&#x3b4;, and thus these compounds can be used for treating diseases related to PI3K pathway, especially for anti-cancer or for the treatment of tumors, leukemias and autoimmune diseases. After further optimizing and screening, the compounds are expected to be developed into a new type of anti-tumor drugs.

7-site substituted pyrrole triazine compounds or pharmaceutically acceptable salts thereof, and preparation method thereof and uses thereof

Human antibodies which specifically bind to human CTLA-4, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

CTLA-4 antibodies and uses thereof

Examples include techniques for backing up a file to long term 'cold' storage by using circuitry, and logic for execution by the circuitry, to receive a request to back up the file in a distributed file system to cold storage, to copy the file from at least one data node of the distributed file system to cold storage, to set a location of the file in cold storage in a name node of the distributed file system, and to set a length of the file to zero in the name node.

Method of efficient backup of distributed file system files with transparent data access

Disclosed are a 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, a preparation method therefor and an application thereof. Specifically, disclosed are three crystalline forms, i.e., crystalline forms A, B, and C, of 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride (formula I), preparation methods for the three crystalline forms, and use of the three crystalline forms in preparation of drugs. 

2-[4-(meihylaminomethyl)phenyl]-5-fluoro- benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof

Growing community of inventors

Shanghai, China

Yi Chen